Valeant Announces Second-Quarter 2017 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Valeant Pharma (VRX) Reports Q2 Loss of $0.11, Adj-EBITDA Beats; Maintains FY EPS, Lowers FY Revs
August 8, 2017 7:06 AM EDTValeant Pharma (NYSE: VRX) reported Q2 EPS of ($0.11), versus ($0.88) reported last year. Revenue for the quarter came in at $2.23 billion, versus $2.42 billion reported last year.
Adjusted EBITDA (non-GAAP) Sequential Increase of 10% to $951 million, beating consensus of $910.8 million.
Second-Quarter 2017 Financial Results
Revenues of $2.233... More